Blood:Wilms'' tumor1基因突变或剂量不足时需额外的基因突变协同诱导白血病发生

2018-08-02 MedSci MedSci原创

中心点:Wt1杂合子会丧失年龄依赖性的干细胞自我更新增强的特性。Wt1-半剂量效应不足白血病需要额外的事件来促进造血转化。摘要:遗传研究已发现在急性髓系白血病(AML)患者中会反复发生体细胞突变,包括WT1(Wilms肿瘤1)基因。WT1突变导致白血病发生的分子机制尚未完全阐明。Elodie Pronier等人对Wt1基因剂量在稳定造血和病理性造血中的作用进行研究。Wt1杂合子会丧失年龄依赖性的干

中心点:

Wt1杂合子会丧失年龄依赖性的干细胞自我更新增强的特性。

Wt1-半剂量效应不足白血病需要额外的事件来促进造血转化。

摘要:

遗传研究已发现在急性髓系白血病(AML)患者中会反复发生体细胞突变,包括WT1(Wilms肿瘤1)基因。WT1突变导致白血病发生的分子机制尚未完全阐明。Elodie Pronier等人对Wt1基因剂量在稳定造血和病理性造血中的作用进行研究。

Wt1杂合子会丧失年龄依赖性的干细胞自我更新增强的特性,Wt1半剂量效应不足白血病的特点是渐进性的遗传和表观遗传改变,包括那些已知的白血病相关的等位基因,表明Wt1半剂量效应不足白血病需要额外的事件(如基因突变)来促进造血转换。与上述结果一致,研究人员还发现Wt1敲除加上Flt3-ITD(Fms样酪氨酸激酶3)突变可诱导完全渗透性AML。

总而言之,本研究为Wt1缺失型白血病的发生机制提供新的见解,并阐述了诱导Wt1半剂量效应不足干/祖细胞转化所需要的额外事件。

原始出处:

Elodie Pronier,et al.Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.Blood  2018  :blood-2018-03-837468;  doi: https://doi.org/10.1182/blood-2018-03-837468

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717436, encodeId=0a091e17436ed, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Fri Apr 12 10:06:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446617, encodeId=9aa3144661e3e, content=<a href='/topic/show?id=47dc1e93622' target=_blank style='color:#2F92EE;'>#Tumor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17936, encryptionId=47dc1e93622, topicName=Tumor)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=eByrP5v1RWUUHNhAmBia6yg&s=100&t=1555405261, createdBy=67fa5252448, createdName=klivis, createdTime=Sat Aug 04 02:06:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336039, encodeId=7a7633603969, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Fri Aug 03 16:16:03 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335773, encodeId=0659335e738f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Aug 02 12:45:17 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335766, encodeId=b1e9335e6641, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Aug 02 12:36:06 CST 2018, time=2018-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717436, encodeId=0a091e17436ed, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Fri Apr 12 10:06:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446617, encodeId=9aa3144661e3e, content=<a href='/topic/show?id=47dc1e93622' target=_blank style='color:#2F92EE;'>#Tumor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17936, encryptionId=47dc1e93622, topicName=Tumor)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=eByrP5v1RWUUHNhAmBia6yg&s=100&t=1555405261, createdBy=67fa5252448, createdName=klivis, createdTime=Sat Aug 04 02:06:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336039, encodeId=7a7633603969, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Fri Aug 03 16:16:03 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335773, encodeId=0659335e738f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Aug 02 12:45:17 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335766, encodeId=b1e9335e6641, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Aug 02 12:36:06 CST 2018, time=2018-08-02, status=1, ipAttribution=)]
    2018-08-04 klivis
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717436, encodeId=0a091e17436ed, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Fri Apr 12 10:06:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446617, encodeId=9aa3144661e3e, content=<a href='/topic/show?id=47dc1e93622' target=_blank style='color:#2F92EE;'>#Tumor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17936, encryptionId=47dc1e93622, topicName=Tumor)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=eByrP5v1RWUUHNhAmBia6yg&s=100&t=1555405261, createdBy=67fa5252448, createdName=klivis, createdTime=Sat Aug 04 02:06:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336039, encodeId=7a7633603969, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Fri Aug 03 16:16:03 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335773, encodeId=0659335e738f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Aug 02 12:45:17 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335766, encodeId=b1e9335e6641, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Aug 02 12:36:06 CST 2018, time=2018-08-02, status=1, ipAttribution=)]
    2018-08-03 lietome2

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1717436, encodeId=0a091e17436ed, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Fri Apr 12 10:06:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446617, encodeId=9aa3144661e3e, content=<a href='/topic/show?id=47dc1e93622' target=_blank style='color:#2F92EE;'>#Tumor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17936, encryptionId=47dc1e93622, topicName=Tumor)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=eByrP5v1RWUUHNhAmBia6yg&s=100&t=1555405261, createdBy=67fa5252448, createdName=klivis, createdTime=Sat Aug 04 02:06:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336039, encodeId=7a7633603969, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Fri Aug 03 16:16:03 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335773, encodeId=0659335e738f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Aug 02 12:45:17 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335766, encodeId=b1e9335e6641, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Aug 02 12:36:06 CST 2018, time=2018-08-02, status=1, ipAttribution=)]
    2018-08-02 183****7028

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1717436, encodeId=0a091e17436ed, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Fri Apr 12 10:06:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446617, encodeId=9aa3144661e3e, content=<a href='/topic/show?id=47dc1e93622' target=_blank style='color:#2F92EE;'>#Tumor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17936, encryptionId=47dc1e93622, topicName=Tumor)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=eByrP5v1RWUUHNhAmBia6yg&s=100&t=1555405261, createdBy=67fa5252448, createdName=klivis, createdTime=Sat Aug 04 02:06:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336039, encodeId=7a7633603969, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Fri Aug 03 16:16:03 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335773, encodeId=0659335e738f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Aug 02 12:45:17 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335766, encodeId=b1e9335e6641, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Aug 02 12:36:06 CST 2018, time=2018-08-02, status=1, ipAttribution=)]
    2018-08-02 sunfeifeiyang

    0

相关资讯

Blood:树突细胞疫苗可以预防或延迟AML缓解期患者复发。

复发是急性髓性白血病(AML)的主要问题,严重影响患者的存活期。现有研究发现,电转WT1-mRNA的树突细胞疫苗可以在一定程度上预防或延缓AML缓解期患者复发急性白血病。

Blood:接种疫苗可增强靶向胞内致癌WT1的CAR-T细胞的抗肿瘤效果!

近期,嵌合抗原受体(CAR)-T细胞治疗血液恶性肿瘤的成功,为进一步开发治疗液体和固体肿瘤的疗法提供了支持。但是,因需要保护正常细胞,CAR-T细胞疗法的扩展受肿瘤表面特异性抗原的可用性限制。虽然细胞内表达多种蛋白,含有大量的肿瘤抗原,但目前和传统的CAR-T细胞均不能以其为靶点。而且,适应性移植的T细胞常出现衰竭和扩展不足,部分是由于机体的免疫抑制。因此,我们需要开发新的方法来进一步激活扩增体内